Feature Article

Bronchiectasis: a new dawn in diagnosis and treatment





1.    Cotran RS, Kumar V, Collins T, Robbins SL. Bronchiectasis. In: Cotran RS, ed. Robbins pathologic basis of disease. Philadelphia: Saunders; 1999.
2.    Chang AB, Bell SC, Torzillo PJ, et al. Thoracic Society of Australia and  New Zealand (TSANZ). Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Clinical Practice Guideline, October 2014. Sydney: TSANZ; 2014. Available online at: SuppurativeLungDisease-Guidelines-2016-web.pdf (accessed March 2019).
3.    Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50(3). pii: 1700629.
4.    Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010; 193: 356-365.
5.    de la Rosa Carrillo D, Navarro Rolon A, Giron Moreno RM, et al. Cost of hospitalizations due to exacerbation in patients with non-cystic fibrosis bronchiectasis. Respiration 2018: 96: 406-416.
6.    Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831.
7.    Navaratnam V, Root AA, Douglas I, Smeeth L, Hubbard RB, Quint JK. Cardiovascular outcomes after a respiratory tract infection among adults with non-cystic fibrosis bronchiectasis: a general population-based study. Ann Am Thorac Soc 2018; 15: 315-321.
8.    Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2015;  10: 1465-1475.
9.    Padilla-Galo A, Olveira C, Fernandez de Rota-Garcia L, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res 2018; 19: 43.
10.    Basnayake TL, Morgan LC, Chang AB. The global burden of respiratory infections in indigenous children and adults: a review. Respirology 2017;  22: 1518-1528.
11.    McCallum GB, Binks MJ. The epidemiology of chronic suppurative lung disease and bronchiectasis in children and adolescents. Front Pediatr 2017; 5: 27.
12.    Garcia MA, Cataluna JJ. [Chronic obstructive pulmonary disease and bronchiectasias]. Arch Bronconeumol 2010; 46 Suppl 3: 11-17.
13.    Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006; 35: 58-65.
14.    Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849.
15.    Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax 1952; 7: 213-239.
16.    De L’Auscultation Médiate; ou Traite du Diagnostic des Maladies des Poumons et du Coeur, fondé principalement sur ce Nouveau Moyen d’Exploration. Edinb Med Surg J 1822; 18: 447-474.
17.    Maiz L, Giron R, Olveira C, Vendrell M, Nieto R, Martinez-Garcia MA. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study. BMC Infect Dis 2016; 16: 437.
18.    Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest 2017; 151: 982-992.
19.    Araujo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51(2). pii: 1701953.
20.    Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12: 1602-1611.
21.    Blanchette CM, Noone JM, Stone G, et al. Healthcare cost and utilization before and after diagnosis of Pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US. Med Sci (Basel) 2017; 5(4). pii E20.
22.    Mitchelmore P, Wilson C, Hettle D. Risk of bacterial transmission in bronchiectasis outpatient clinics. Curr Pulmonol Rep 2018; 7: 72-78.
23.    Cox MJ, Turek EM, Hennessy C, et al. Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients. PLoS One 2017; 12: e0170622.
24.    Martinez-Garcia MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43: 1357-1367.
25.    Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576-585.
26.    McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax 2016; 71: 1110-1118.
27.    Nogrady SG, Evans WV, Davies BH. Reversibility of airways obstruction in bronchiectasis. Thorax 1978; 33: 635-637.
28.    King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Intern Med J 2006; 36: 729-737.
29.    Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev 2018; (5): CD000996.
30.    Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68: 256-262.
31.    Amaro R, Panagiotaraka M, Alcaraz V, Torres A. The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. Expert Rev Respir Med 2018; 12: 683-691.
32.    Regan KH, Hill AT. Risk of development of resistance in patients with  non-cystic fibrosis bronchiectasis treated with inhaled antibiotics. Curr Pulmonol Rep 2018; 7: 63-71.
33.    Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018; (3): CD012406.
34.    Li W, Qin Z, Gao J, Jiang Z, Chai Y, Guan L, et al. Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison. Chronic Respir Dis 2019; 16: 1479972318790269.


Dr Rangamuwa is an Advanced Trainee in Respiratory Medicine and a Respiratory Registrar at The Alfred Hospital, Melbourne. Associate Professor Stirling is a Senior Specialist in Respiratory Medicine at The Alfred Hospital, Melbourne; and a Clinical Adjunct Associate Professor in the Department of Medicine, Monash University, Melbourne, Vic.